{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:33:08Z","timestamp":1790685188934,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Helse Vest, Haukeland University Hospital"},{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Norwegian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"name":"K.G. Jebsen Research Foundation"},{"name":"Bergen Medical Research Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Suicide gene therapy for malignant gliomas has shown encouraging results in the latest clinical trials. However, prodrug application was most often restricted to short-term treatment (14 days), especially when replication-defective vectors were used. We previously showed that a substantial fraction of herpes simplex virus thymidine kinase (HSV-TK) transduced tumor cells survive ganciclovir (GCV) treatment in an orthotopic glioblastoma (GBM) xenograft model. Here we analyzed whether these TK+ tumor cells are still sensitive to prodrug treatment and whether prolonged prodrug treatment can enhance treatment efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Glioma cells positive for TK and green fluorescent protein (GFP) were sorted from xenograft tumors recurring after suicide gene therapy, and their sensitivity to GCV was tested in vitro. GBM xenografts were treated with HSV-TK\/GCV, HSV-TK\/valganciclovir (valGCV), or HSV-TK\/valGCV + erlotinib. Tumor growth was analyzed by MRI, and survival as well as morphological and molecular changes were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TK-GFP+ tumor cells from recurrent xenograft tumors retained sensitivity to GCV in vitro. Importantly, a prolonged period (3 mo) of prodrug administration with valganciclovir (valGCV) resulted in a significant survival advantage compared with short-term (3 wk) application of GCV. Recurrent tumors from the treatment groups were more invasive and less angiogenic compared with primary tumors and showed significant upregulation of epidermal growth factor receptor (EGFR) expression. However, double treatment with the EGFR inhibitor erlotinib did not increase therapeutic efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Long-term treatment with valGCV should be considered as a replacement for short-term treatment with GCV in clinical trials of HSV-TK mediated suicide gene therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noz060","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T09:32:34Z","timestamp":1554283954000},"page":"890-900","source":"Crossref","is-referenced-by-count":28,"title":["Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma"],"prefix":"10.1093","volume":"21","author":[{"given":"Jubayer A","family":"Hossain","sequence":"first","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"},{"name":"Department of Pathology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md A","family":"Latif","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"},{"name":"Department of Pathology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars A R","family":"Ystaas","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ninzima","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"},{"name":"Department of Pathology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Riecken","sequence":"additional","affiliation":[{"name":"Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Muller","sequence":"additional","affiliation":[{"name":"Bioinformatics Team, Center for Quantitative Biology, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Azuaje","sequence":"additional","affiliation":[{"name":"Bioinformatics Team, Center for Quantitative Biology, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin V","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna M","family":"Talasila","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwan","family":"Ghimire","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Fehse","sequence":"additional","affiliation":[{"name":"Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Bjerkvig","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"},{"name":"Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrvoje","family":"Miletic","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, University of Bergen, Bergen, Norway"},{"name":"Department of Pathology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"issue":"10","key":"2019071105355299800_CIT0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"6190","key":"2019071105355299800_CIT0002","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science."},{"issue":"12","key":"2019071105355299800_CIT0003","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/nm1297-1354","article-title":"Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells","volume":"3","author":"Ram","year":"1997","journal-title":"Nat Med."},{"issue":"14","key":"2019071105355299800_CIT0004","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1089\/10430349950016979","article-title":"A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group","volume":"10","author":"Shand","year":"1999","journal-title":"Hum Gene Ther."},{"issue":"3","key":"2019071105355299800_CIT0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/B:NEON.0000003652.71665.f2","article-title":"Clinical trials with retrovirus mediated gene therapy\u2014what have we learned?","volume":"65","author":"Rainov","year":"2003","journal-title":"J Neurooncol."},{"issue":"17","key":"2019071105355299800_CIT0006","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1089\/104303400750038499","article-title":"A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme","volume":"11","author":"Rainov","year":"2000","journal-title":"Hum Gene Ther."},{"issue":"5259","key":"2019071105355299800_CIT0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science."},{"issue":"7","key":"2019071105355299800_CIT0008","doi-asserted-by":"crossref","first-page":"e6314","DOI":"10.1371\/journal.pone.0006314","article-title":"Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy","volume":"4","author":"Huszthy","year":"2009","journal-title":"PLoS One."},{"issue":"9","key":"2019071105355299800_CIT0009","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jgm.2895","article-title":"Lentiviral HSV-Tk.007-mediated suicide gene therapy is not toxic for normal brain cells","volume":"18","author":"Hossain","year":"2016","journal-title":"J Gene Med."},{"issue":"22 Pt 1","key":"2019071105355299800_CIT0010","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1158\/1078-0432.CCR-07-1240","article-title":"Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma","volume":"13","author":"Miletic","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"44","key":"2019071105355299800_CIT0011","doi-asserted-by":"crossref","first-page":"16466","DOI":"10.1073\/pnas.0607668103","article-title":"Angiogenesis-independent tumor growth mediated by stem-like cancer cells","volume":"103","author":"Sakariassen","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2019071105355299800_CIT0012","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3171\/jns.1990.72.3.0463","article-title":"Multicellular tumor spheroids from human gliomas maintained in organ culture.","volume":"72","author":"Bjerkvig","year":"1990","journal-title":"J Neurosurg."},{"issue":"12","key":"2019071105355299800_CIT0013","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/neuonc\/now113","article-title":"EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation","volume":"18","author":"Eskilsson","year":"2016","journal-title":"Neuro Oncol."},{"key":"2019071105355299800_CIT0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-8922-5_2","article-title":"Cancer suicide gene therapy with TK.007","volume":"1895","author":"Hossain","year":"2019","journal-title":"Methods Mol Biol."},{"issue":"11","key":"2019071105355299800_CIT0015","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00109-011-0777-8","article-title":"Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect","volume":"89","author":"Preuss","year":"2011","journal-title":"J Mol Med (Berl)."},{"issue":"8","key":"2019071105355299800_CIT0016","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/hum.2009.042","article-title":"TK.007: a novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy","volume":"21","author":"Preuss","year":"2010","journal-title":"Hum Gene Ther."},{"issue":"9","key":"2019071105355299800_CIT0017","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","article-title":"Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial","volume":"14","author":"Westphal","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2\u20133","key":"2019071105355299800_CIT0018","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Research."},{"issue":"5","key":"2019071105355299800_CIT0019","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ijc.28111","article-title":"Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study","volume":"133","author":"Stragliotto","year":"2013","journal-title":"Int J Cancer."},{"issue":"9","key":"2019071105355299800_CIT0020","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1093\/cid\/cir257","article-title":"Guidelines for the prevention of intravascular catheter-related infections","volume":"52","author":"O\u2019Grady","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"1","key":"2019071105355299800_CIT0021","first-page":"83","article-title":"In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats","volume":"53","author":"Ram","year":"1993","journal-title":"Cancer Res."},{"issue":"17","key":"2019071105355299800_CIT0022","first-page":"2595","article-title":"A phase I\/II study of herpes simplex virus type 1 thymidine kinase \u201csuicide\u201d gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma","volume":"9","author":"Klatzmann","year":"1998","journal-title":"Hum Gene Ther."},{"issue":"1","key":"2019071105355299800_CIT0023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1215\/15228517-2007-045","article-title":"Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model","volume":"10","author":"King","year":"2008","journal-title":"Neuro Oncol."},{"issue":"5","key":"2019071105355299800_CIT0024","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ymthe.2004.08.002","article-title":"AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study","volume":"10","author":"Immonen","year":"2004","journal-title":"Mol Ther."},{"issue":"8","key":"2019071105355299800_CIT0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/neuonc\/nos135","article-title":"In vivo models of primary brain tumors: pitfalls and perspectives","volume":"14","author":"Huszthy","year":"2012","journal-title":"Neuro Oncol."},{"issue":"12","key":"2019071105355299800_CIT0026","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2004-03-0852","article-title":"Tumor cells escape suicide gene therapy by genetic and epigenetic instability","volume":"104","author":"Frank","year":"2004","journal-title":"Blood."},{"issue":"10","key":"2019071105355299800_CIT0027","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1128\/MCB.15.10.5322","article-title":"A truncated herpes simplex virus thymidine kinase phosphorylates thymidine and nucleoside analogs and does not cause sterility in transgenic mice","volume":"15","author":"Salomon","year":"1995","journal-title":"Mol Cell Biol."},{"issue":"2","key":"2019071105355299800_CIT0028","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/mthe.2001.0433","article-title":"Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene","volume":"4","author":"Chalmers","year":"2001","journal-title":"Mol Ther."},{"issue":"3","key":"2019071105355299800_CIT0029","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.49.3.1055-1059.2005","article-title":"Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study","volume":"49","author":"Frobert","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"2019071105355299800_CIT0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/00003495-200565060-00012","article-title":"Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients","volume":"65","author":"Cvetkovi\u0107","year":"2005","journal-title":"Drugs."},{"issue":"3","key":"2019071105355299800_CIT0031","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12","author":"de Groot","year":"2010","journal-title":"Neuro Oncol."},{"issue":"9","key":"2019071105355299800_CIT0032","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1073\/pnas.1014480108","article-title":"Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma","volume":"108","author":"Keunen","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2019071105355299800_CIT0033","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell."},{"issue":"6","key":"2019071105355299800_CIT0034","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.MAT.0000093747.89681.4C","article-title":"Lentiviral vector: a useful tool for transduction of human liver endothelial cells","volume":"49","author":"Totsugawa","year":"2003","journal-title":"ASAIO J."},{"issue":"1","key":"2019071105355299800_CIT0035","first-page":"19","article-title":"Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells","volume":"1","author":"Radinsky","year":"1995","journal-title":"Clin Cancer Res."},{"key":"2019071105355299800_CIT0036","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-9966-29-16","article-title":"Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis","volume":"29","author":"Liu","year":"2010","journal-title":"J Exp Clin Cancer Res."},{"issue":"7249","key":"2019071105355299800_CIT0037","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","article-title":"Genes that mediate breast cancer metastasis to the brain","volume":"459","author":"Bos","year":"2009","journal-title":"Nature."},{"issue":"2","key":"2019071105355299800_CIT0038","first-page":"413","article-title":"Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas","volume":"63","author":"Okada","year":"2003","journal-title":"Cancer Res."},{"issue":"5","key":"2019071105355299800_CIT0039","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1101-1","article-title":"EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis","volume":"125","author":"Talasila","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2019071105355299800_CIT0040","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/JTO.0b013e3181e2138b","article-title":"Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer","volume":"5","author":"Togashi","year":"2010","journal-title":"J Thorac Oncol."},{"issue":"11","key":"2019071105355299800_CIT0041","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","article-title":"Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib","volume":"4","author":"Katayama","year":"2009","journal-title":"J Thorac Oncol."},{"issue":"5","key":"2019071105355299800_CIT0042","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/1078-0432.CCR-06-2372","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420","volume":"13","author":"Broniscer","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2019071105355299800_CIT0043","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet."},{"issue":"8","key":"2019071105355299800_CIT0044","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/nn.4584","article-title":"A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma","volume":"20","author":"Guo","year":"2017","journal-title":"Nat Neurosci."},{"issue":"5","key":"2019071105355299800_CIT0045","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/2159-8290.CD-12-0502","article-title":"De-repression of PDGFR\u03b2 transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients","volume":"3","author":"Akhavan","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"2019071105355299800_CIT0046","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/labinvest.2015.140","article-title":"WNT signaling in glioblastoma and therapeutic opportunities","volume":"96","author":"Lee","year":"2016","journal-title":"Lab Invest."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noz060\/28558429\/noz060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/21\/7\/890\/28926218\/noz060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T19:59:20Z","timestamp":1569355160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/21\/7\/890\/5431345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4,8]]},"published-print":{"date-parts":[[2019,7,11]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noz060","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,4,8]]}}}